ArticlePediatric cardiology2026
Diagnostic Utility of Prominent Mid-Precordial Lead Voltage in a Pediatric Population.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
ECG criteria for diagnosing chamber enlargement has poor predictive value. Elevated voltages in mid-precordial leads may have clinical utility and we hypothesized that ECGs with a single mid-precordial voltage ≥ 60 mV correlate with congenital heart disease (CHD) in a pediatric cohort. This was a retrospective analysis of pediatric ECGs at the University of Minnesota from 2006 to 2021. Included patients had a single mid-precordial lead (V2-V5) QRS voltage ≥ 60 mV and an echocardiogram within 1 month. ECG parameters including rhythm, atrial enlargement, axis deviation, hypertrophy criteria and echocardiogram findings were evaluated. Of 122 patients (mean 1.6 ± 2.5 years, 62% male), seventeen (14%) (mean 2.5 ± 3.0 years) had normal anatomy and 105 (86%) (mean 1.5 ± 2.4 years) had CHD. Mean maximum QRS voltage was 75.9 ± 13.5 mV with a significantly higher mean maximum voltage in the CHD versus control group (77.0 ± 13.7 vs 69.2 ± 9.7 mV, p = 0.012). A receiver operating characteristic curve for maximum QRS voltage had an AUC of 0.691 (95% CI 0.546-0.835). 66.5 mV had the best sensitivity (76%) and specificity (59%) combination and a value of 92.5 mV had a specificity of 100% for CHD. A QRS voltage of 60 mV in mid-precordial leads was associated with CHD in a cohort of pediatric patients. Echocardiograms remain reasonable in these patients though larger cohort studies are needed to develop ideal cutoffs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.